Janux Therapeutics (NASDAQ:JANX) Receives Outperform Rating from William Blair

William Blair reissued their outperform rating on shares of Janux Therapeutics (NASDAQ:JANX) in a research report released on Friday,RTT News reports.

Other equities research analysts also recently issued research reports about the stock. Lifesci Capital raised shares of Janux Therapeutics to a “strong-buy” rating in a research report on Friday, December 27th. Stifel Nicolaus upped their price target on shares of Janux Therapeutics from $70.00 to $115.00 and gave the stock a “buy” rating in a research report on Tuesday, December 3rd. Leerink Partners upped their price objective on Janux Therapeutics from $79.00 to $91.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 3rd. UBS Group started coverage on Janux Therapeutics in a research report on Thursday, October 24th. They set a “buy” rating and a $69.00 target price for the company. Finally, BTIG Research boosted their price target on Janux Therapeutics from $82.00 to $100.00 and gave the stock a “buy” rating in a report on Tuesday, December 3rd. One equities research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $89.90.

Janux Therapeutics Price Performance

JANX stock opened at $46.76 on Friday. Janux Therapeutics has a 1 year low of $7.79 and a 1 year high of $71.71. The company has a market cap of $2.45 billion, a P/E ratio of -39.97 and a beta of 3.23. The stock’s fifty day moving average price is $54.26 and its 200-day moving average price is $48.31.

Janux Therapeutics (NASDAQ:JANX) last announced its earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.18). Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The firm had revenue of $0.44 million during the quarter, compared to analysts’ expectations of $1.50 million. Janux Therapeutics’s revenue for the quarter was down 82.6% compared to the same quarter last year. As a group, analysts expect that Janux Therapeutics will post -1.35 earnings per share for the current year.

Insiders Place Their Bets

In other Janux Therapeutics news, Director Ra Capital Management, L.P. acquired 1,200,000 shares of the company’s stock in a transaction on Friday, October 18th. The stock was acquired at an average cost of $44.75 per share, with a total value of $53,700,000.00. Following the purchase, the director now directly owns 9,317,246 shares of the company’s stock, valued at approximately $416,946,758.50. This represents a 14.78 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO David Alan Campbell sold 5,000 shares of the company’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $60.00, for a total transaction of $300,000.00. Following the sale, the chief executive officer now owns 293,054 shares in the company, valued at $17,583,240. This represents a 1.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 110,177 shares of company stock valued at $6,162,207 in the last quarter. 29.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Janux Therapeutics

Institutional investors have recently made changes to their positions in the company. Charles Schwab Investment Management Inc. grew its position in Janux Therapeutics by 202.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 234,191 shares of the company’s stock valued at $10,639,000 after acquiring an additional 156,675 shares during the last quarter. Ally Bridge Group NY LLC purchased a new stake in shares of Janux Therapeutics during the third quarter valued at $4,943,000. Algert Global LLC bought a new position in shares of Janux Therapeutics in the third quarter worth about $1,112,000. FMR LLC increased its stake in Janux Therapeutics by 0.6% in the 3rd quarter. FMR LLC now owns 7,824,675 shares of the company’s stock worth $355,475,000 after buying an additional 47,075 shares during the period. Finally, Neo Ivy Capital Management bought a new stake in Janux Therapeutics during the 3rd quarter valued at about $940,000. Institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.